MediWound Ltd. - Ordinary Shares (MDWD) analyst actions
Rating and price-target actions on MDWD in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MDWD overview →
1 measured MDWD analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers | Press release | -0.15% | +4.44% |
Keep exploring
More MDWD: earnings → · SEC filings → · MDWD overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CymaBay Therapeutics Inc. (CBAY) | 166 | +0.02% | 52% |
| Innoviva, Inc. (INVA) | 166 | +0.10% | 54% |
| XBiotech Inc. (XBIT) | 165 | 0.00% | 45% |
| Minerva Neurosciences, Inc (NERV) | 164 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.